Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector
- PMID: 10022536
- DOI: 10.1089/10430349950019246
Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector
Abstract
Replication-deficient adenoviral vectors have been developed for the delivery of DNA sequences encoding a variety of proteins intended for the management of disease through gene therapy. One concern is the occurrence of replication-competent adenovirus (RCA) in the population of replication-deficient adenoviral vectors as a result of recombination or contamination. To address this concern, it is necessary to determine the frequency of occurrence and to fully characterize the molecular structure and biological infectivity of RCA. rAd/p53 is a pIX-deleted p53 gene therapy vector that is designed to lower the RCA occurrence and to deliver the tumor suppressor gene p53 for treatment of various cancers. Multiple preparations of the replication-deficient adenoviral vector rAd/p53 were tested for the presence of RCA, employing a sensitive biological assay. Single plaques from RCA-positive preparations of rAd/p53 were isolated for molecular characterization. All of the RCA isolates displayed a single unique structure that contains the complete E1 sequence of adenovirus type 5 but lacks the p53 sequence. The detailed sequence analysis of the RCA suggests that it is most likely generated as a result of recombination events between the rAd/p53 DNA and the 293 host adenoviral sequence. Results from viral infectivity analysis by flow cytometry demonstrate no substantial difference in infectivity of RCA, rAd/p53, and wild-type adenovirus type 5 in 293 cells.
Similar articles
-
New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.Hum Gene Ther. 1998 Sep 1;9(13):1909-17. doi: 10.1089/hum.1998.9.13-1909. Hum Gene Ther. 1998. PMID: 9741429
-
Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors.Gene Ther. 1996 Jan;3(1):75-84. Gene Ther. 1996. PMID: 8929914
-
Genetically modified adenoviruses against gliomas: from bench to bedside.Neurology. 2004 Aug 10;63(3):418-26. doi: 10.1212/01.wnl.0000133302.15022.7f. Neurology. 2004. PMID: 15304571 Review.
-
A simple method for the simultaneous detection of E1A and E1B in adenovirus stocks.Oncol Rep. 2004 Jan;11(1):173-8. Oncol Rep. 2004. PMID: 14654922
-
Mutant adenoviruses selectively replication-competent in tumor cells.Adv Exp Med Biol. 2000;465:65-71. doi: 10.1007/0-306-46817-4_7. Adv Exp Med Biol. 2000. PMID: 10810616 Review. No abstract available.
Cited by
-
Adenoviral Gene Therapy Vectors in Clinical Use-Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety.Int J Mol Sci. 2023 Nov 20;24(22):16519. doi: 10.3390/ijms242216519. Int J Mol Sci. 2023. PMID: 38003709 Free PMC article. Review.
-
Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches.J Virol. 2004 Jun;78(12):6200-8. doi: 10.1128/JVI.78.12.6200-6208.2004. J Virol. 2004. PMID: 15163713 Free PMC article.
-
A Method to Generate and Rescue Recombinant Adenovirus Devoid of Replication-Competent Particles in Animal-Origin-Free Culture Medium.Viruses. 2023 Oct 25;15(11):2152. doi: 10.3390/v15112152. Viruses. 2023. PMID: 38005830 Free PMC article.
-
Current Status of Poultry Recombinant Virus Vector Vaccine Development.Vaccines (Basel). 2024 Jun 6;12(6):630. doi: 10.3390/vaccines12060630. Vaccines (Basel). 2024. PMID: 38932359 Free PMC article. Review.
-
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.Viruses. 2012 Nov 1;4(11):2711-35. doi: 10.3390/v4112711. Viruses. 2012. PMID: 23202501 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous